Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.
Also called NCT01838850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
- Registry
-
NCT01838850
-
- Other papers using this trial's data
- Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01838850. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
- Condition
- Essential Hypertension
- Intervention (Drug)
- CS8635 20/5/12.5mg and placebo
- Intervention (Drug)
- Olmetec® Plus 20/12.5mg and placebo
- Lead sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Record details
- Record id
cardio:ct-nct01838850- Content hash
4f96aac04c2a214bbac5a86fa1585711ace232012bb56b9160c8bbc1f8f8b71c